# Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct05317819/  
OnCo record `nct05317819` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing ADI-PEG20 in hepatocellular carcinoma, now recruiting.

## Summary

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT05317819, led by Polaris, and recruiting on the registry. Official title: A Randomised, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma. Planned enrolment is 300 participants (estimated). The study started in 2022-03-14 and primary completion is expected in 2028-09. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05317819
- Phase: 3
- Setting: A Randomized, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
- Sponsor: Polaris
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT05317819: https://clinicaltrials.gov/study/NCT05317819

## Connected records

- cancers: [Advanced hepatocellular carcinoma (BCLC C)](https://onco.cc/cancers/hcc-advanced/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [ADI-PEG20](https://onco.cc/drugs/adi-peg20/)
- companies: [Polaris Group](https://onco.cc/companies/polaris-group/)

---
JSON: https://onco.cc/api/v1/entities/nct05317819.json